| 195.7375 -1.459 (-0.74%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 231.35 | 1-year : | 270.22 |
| Resists | First : | 198.08 | Second : | 231.35 |
| Pivot price | 192.9  |
|||
| Supports | First : | 185.26 |
Second : | 177.35 |
| MAs | MA(5) : | 195.98 |
MA(20) : | 190.72 |
| MA(100) : | 172.6 |
MA(250) : | 0 | |
| MACD | MACD : | 4.6 |
Signal : | 4.6 |
| %K %D | K(14,3) : | 83.5 |
D(3) : | 83.7 |
| RSI | RSI(14): 67.2 |
|||
| 52-week | High : | 198.08 | Low : | 135.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BBH ] has closed below upper band by 29.9%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 197.29 - 198.32 | 198.32 - 199.21 |
| Low: | 192.41 - 193.6 | 193.6 - 194.61 |
| Close: | 193.79 - 195.8 | 195.8 - 197.52 |
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Wed, 03 Dec 2025
AI in Pharma and Biotech: Market Trends 2025 and Beyond - VanEck
Tue, 02 Dec 2025
AI in Pharma and Biotech: Market Trends 2025 and Beyond - VanEck
Tue, 25 Nov 2025
AI in Pharma and Biotech: Market Trends 2025 and Beyond - VanEck
Thu, 02 Oct 2025
The Best Biotech ETFs to Buy - Kiplinger
Mon, 01 Sep 2025
BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH (NASDAQ:IBB) - Seeking Alpha
Wed, 13 Aug 2025
7 Best Biotech ETFs to Buy Now - US News Money
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|